Folinic acid (leucovorin)
What studies of folinic acid (leucovorin) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Folinic acid (leucovorin) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Folinic acid (leucovorin) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Daily life and health overall
Overall symptoms1 study · 42 people took folinic acid (leucovorin) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (42 in all); not all results were tested against chance.
Studies with no comparison group58 in the study · 42 started · 42 with outcome data · 1−2 months · 25 mg dose level, 3−4 times daily for 1−2 months
Overall symptoms improved.
The evidence is very uncertain about the effect of folinic acid (leucovorin) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (42 in all)
- Not all results were tested against chance
See the 1 study
-
Clinical activity of folinic acid in patients with chronic fatigue syndrome. (2006)
- People in the study
- 58 in the study · 42 started · 42 with outcome data
- Dose
- 25 mg dose level, 3−4 times daily for 1−2 months
- Outcome
- improvement with increased energy level and reduced pain
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 mg at the start
- 2Top dose
Most often 25 mg (1 of 1 studies)
Doses across 1 study
25 to 25 mg.
Each study’s dose, as printed
- 25 mg dose level, 3−4 times daily for 1−2 months Clinical activity of folinic acid in patients with chronic fatigue syndrome. (2006)
All papers
- Clinical activity of folinic acid in patients with chronic fatigue syndrome.2006 · no comparison group · 58 in the study · 42 started · 42 with outcome data
Summary
This retrospective study evaluated 58 patients with chronic fatigue syndrome (CFS) at the Parker Hughes Institute and Parker Hughes Clinics, St. Paul, MN (USA). Forty-two patients were empirically treated with oral folinic acid at a 25 mg dose level 3−4 times daily for 1−2 months; patients were interviewed about effects on fatigue and pain. There was no comparison group. Within 2 months, 34 patients (81 %) reported significant subjective improvement with increased energy level and reduced pain. Table 4 reported improvement after folinic acid in 14 of 20 (70 %) with CFS or CFS plus FM, 6 of 8 (75 %) with CFS plus IBD, 8 of 8 (100 %) with CFS plus RA, 5 of 5 (100 %) with CFS plus SLE, 1 with CFS plus MS, 10 of 13 (77 %) with EA IgG−, and 24 of 29 (83 %) with EA IgG+. Several patients also reported improvement in numbness of their hands and feet. No patient reported side effects from folinic acid. The paper does not report withdrawals for harms, worsening, or stopping treatment. The authors state that folic acid deficiency was not examined using serum folate measurements.